A few days after the court hearing on an injunction was mysteriously delayed, the settlement of their patent fight over drugs for insulin-like growth factor 1 deficiency is not only taking Insmed Inc.'s Iplex off the market for short stature - decisively clearing the path for Tercica Inc. (along with licensor Genentech Inc.) to market Increlex - but also provides opt-in possibilities that continue their relationship in other indications. (BioWorld Today)
Less than two months after Phase II success with its insomnia drug, privately held Hypnion Inc. is being taken over by Eli Lilly and Co. for undisclosed terms. (BioWorld Today)
The potential multiple-sclerosis application of Vaccinex Inc.'s preclinical antibody VX15 drew interest from Teva Pharmaceuticals Inc., which is taking part in an anticipated $25 million-plus financing round while entering a deal with Vaccinex to develop and sell the drug. (BioWorld Today)
